Tudor Investment Corp ET AL Invests $1.35 Million in Celcuity, Inc. $CELC

Tudor Investment Corp ET AL bought a new stake in Celcuity, Inc. (NASDAQ:CELC) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 27,340 shares of the company’s stock, valued at approximately $1,351,000. Tudor Investment Corp ET AL owned approximately 0.06% of Celcuity at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of CELC. US Bancorp DE raised its stake in Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after acquiring an additional 143 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Celcuity by 1.2% in the second quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock valued at $570,000 after buying an additional 503 shares during the last quarter. Ogorek Anthony Joseph NY ADV acquired a new stake in shares of Celcuity during the third quarter worth about $27,000. Intech Investment Management LLC boosted its stake in shares of Celcuity by 5.2% during the second quarter. Intech Investment Management LLC now owns 14,855 shares of the company’s stock worth $198,000 after buying an additional 734 shares during the period. Finally, BNP Paribas Financial Markets grew its holdings in shares of Celcuity by 78.9% during the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock worth $35,000 after buying an additional 1,167 shares during the last quarter. 63.33% of the stock is owned by hedge funds and other institutional investors.

Celcuity Stock Performance

Shares of CELC stock opened at $106.02 on Monday. The company has a market cap of $5.13 billion, a price-to-earnings ratio of -27.97 and a beta of 0.38. The stock has a 50 day simple moving average of $109.49 and a 200-day simple moving average of $91.20. Celcuity, Inc. has a 12-month low of $7.57 and a 12-month high of $120.32. The company has a current ratio of 10.55, a quick ratio of 10.55 and a debt-to-equity ratio of 3.20.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings results on Wednesday, March 25th. The company reported ($0.97) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.09. On average, equities analysts forecast that Celcuity, Inc. will post -2.62 EPS for the current year.

Insider Buying and Selling

In other Celcuity news, Director David Dalvey sold 20,000 shares of the firm’s stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total value of $2,400,600.00. Following the completion of the sale, the director owned 90,000 shares of the company’s stock, valued at approximately $10,802,700. This trade represents a 18.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 15.78% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on CELC. Wall Street Zen upgraded Celcuity from a “sell” rating to a “hold” rating in a research report on Saturday. Needham & Company LLC reaffirmed a “buy” rating and set a $122.00 price objective on shares of Celcuity in a research report on Thursday. Wolfe Research reiterated an “outperform” rating and issued a $110.00 target price on shares of Celcuity in a research note on Thursday, March 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Celcuity in a report on Wednesday, January 21st. Finally, Jefferies Financial Group increased their price target on Celcuity from $108.00 to $134.00 and gave the stock a “buy” rating in a report on Tuesday, December 2nd. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Celcuity has an average rating of “Moderate Buy” and an average price target of $109.88.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.